Therapeutic Response to Myosin Inhibitor Therapy in Noonan Syndrome–Associated Obstructive Hypertrophic Cardiomyopathy

Key Points

• Myosin inhibitor therapy may benefit obstructive hypertrophic cardiomyopathy in Noonan syndrome, indicating potential for targeted treatments.
• Current findings support unique therapeutic approaches for syndromic HOCM associated with Noonan syndrome.
• Observational analysis highlights the promise of myosin inhibitors for HOCM, with further studies warranted to confirm outcomes.
• Identifying effective interventions in syndromic HOCM underscores the need for additional research efforts.